New Grant to Study Congenital Cytomegalovirus Infection

Understanding Immune System Protection

A University of Minnesota Medical School research team has received a 5-year, $3.87 million grant from the National Institutes of Health. The grant, awarded to Mark Schleiss, MD, will fund research into how the immune system protects against congenital cytomegalovirus (CMV) infection.

Congenital CMV infection is a leading cause of birth defects and developmental disabilities. The research aims to understand how the maternal immune system responds to CMV infection during pregnancy. This knowledge could lead to the development of new treatments and prevention strategies.

Can a Vaccine be Developed?

The research team will investigate how the immune system protects against CMV infection. They will study the role of antibodies and other immune factors in preventing the virus from being transmitted to the fetus. The team hopes to identify potential targets for vaccine development.

Dr. Schleiss's team will use a combination of laboratory and clinical research to study the immune response to CMV infection. They will analyze data from pregnant women who have been infected with CMV to understand how their immune systems respond to the virus.

The research has the potential to lead to the development of a vaccine against congenital CMV infection. If successful, the vaccine could prevent thousands of cases of birth defects and developmental disabilities each year. The grant will allow the team to conduct critical research towards this goal.

Frequently Asked Questions

The study's findings could have significant consequences for public health. A vaccine against CMV could be particularly beneficial for pregnant women and their babies. The research has the potential to improve our understanding of the immune system and its role in protecting against congenital infections.

What is congenital cytomegalovirus infection? Congenital CMV infection occurs when a pregnant woman passes the virus to her fetus. This can cause birth defects and developmental disabilities. How common is congenital CMV infection? Congenital CMV infection is a leading cause of birth defects and developmental disabilities in the US. What are the potential benefits of the research? The research could lead to the development of a vaccine against congenital CMV infection, preventing thousands of cases of birth defects and developmental disabilities.